U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06861075) titled 'CARPEUS : Effect of Carvedilol on the Portosystemic Gradient As Measured by Endoscopic Ultrasound' on Feb. 19.
Brief Summary: The purpose of this study is to assess the efficacy after one month of treatment with Carvedilol (12.5 mg daily) in primary prophylaxis of digestive haemorrhage due to portal hypertension in cirrhosis, by endoscopic ultrasound-guided portal pressure gradient measurement.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Cirrhosis
Portal Hypertension Related to Cirrhosis
Intervention:
DRUG: Carvedilol
Carvedilol per os, day 1:3.125 mg once, day 2 to day 8: 6.25 mg/day (3.125 mg twice a da...